Indiana Governor Mike Pence, this morning, signed a bill that targets the dangerous RU 486 abortion drug.
The legislature approved Senate Bill 371, a pro-life bill which introduces oversight into the chemical abortion industry by including chemical abortions in the definition of abortion in Indiana law. Currently, an abortion facility that performs only chemical-type abortions does not have be licensed or inspected. SB 371 will require chemical abortion facilities to meet the same requirements as surgical abortion facilities in such areas as reporting standards, physician oversight, cleanliness standards and building accessibility.
“We heartily thank Governor Pence for affixing his signature to SB 371,” said Mike Fichter, President and CEO of Indiana Right to Life. “SB 371 is a victory for Hoosiers. It is important that abortion facilities adhere to common sense standards for health and that women are provided with appropriate informed consent materials.
Fichter told LifeNews: “Through the passage of SB 371, we believe a situation like the Gosnell ‘House of Horrors’ can be prevented in Indiana. The law requires that chemical abortion facilities undergo inspection and licensing, in the same fashion as surgical abortion facilities. This crucial oversight mechanism will help ensure chemical abortion facilities are ready to adequately care for any woman who experiences complications following her procedure.”
He added, “While SB 371 only affects one current abortion facility that does only chemical abortions, it also prevents additional facilities from moving into Indiana and setting up shop without any oversight.”
According to Indiana Right to Life, when chemical abortion drugs are used up to nine weeks of pregnancy, past the Food and Drug Administration’s seven-week guideline, complication rates drastically rise. According to the New England Journal of Medicine, the failure rate of the chemical abortion drug is 8 percent at 7 weeks, but the failure rises to 23 percent at 9 weeks.
There are also concerns about failed abortions and how they injure women and children — requiring immediate medical attention.
When the abortion is incomplete, facilities needs to be prepared to deal with a woman experiencing uncontrollable bleeding, infection or other potential side effects of the abortion drug. The licensing requirements in SB 371 will establish that chemical abortion facilities maintain an environment appropriate for dealing with these conditions, IRTL says.
Two years ago, the Food and Drug Administration quietly released a report about the deaths of and injuries to women from the dangerous RU 486 abortion drug and the Obama administration did nothing to make the information available to women. The report indicates 14 women in the United States alone have died from using the mifepristone abortion drug and 2,207 women have been injured by it.
Of the women experiencing medical and physical problems resulting from the abortion drug, 612 women required hospitalizations, 339 experienced blood loss significant enough to require a transfusion, 256 experienced infections and 48 women experienced what the FDA labeled as “severe infections.” Given that the RU 486 abortion drug caused sepsis, a potentially lethal infection that resulted in the deaths of women from around the world, the “serious infections” were very likely life-threatening situations.
“Severe infections generally involve death or hospitalization for at least 2-3 days, intravenous antibiotics for at least 24 hours, total antibiotic usage for at least 3 days, and any other physical or clinical findings, laboratory data or surgery that suggest a severe infection,” the FDA report stated.
Women developing infections from usage of the RU 486 abortion drug experienced endometritis (involving the lining of the womb), pelvic inflammatory disease (involving the nearby reproductive organs such as the fallopian tubes or ovaries), and pelvic infections with sepsis (a serious systemic infection that has spread beyond the reproductive organs).
CLICK LIKE IF YOU’RE PRO-LIFE!
The FDA figures also revealed abortion businesses like Planned Parenthood are still misusing the abortion drug.
Despite the FDA indicating, “Administration of mifepristone and misoprostol is contraindicated in patients with confirmed or suspected ectopic pregnancy (a pregnancy outside the uterus,” the abortion drug was given to women in 58 cases where they had an ectopic pregnancy.
Portions of SB 371 go into effective on July 1, 2013 and on January 1, 2014, as specified in the law. SB 371 was introduced by Sen. Travis Holdman (District 19). Reps. Sharon Negele (District 13), Bob Morris (District 84) and Matthew Lehman (District 79) sponsored SB 371 in the Indiana House.
